Abarelix (Plenaxis) for advanced prostate cancer.
D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004342:Drug Hypersensitivity / Q000209:etiology; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D009842:Oligopeptides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011966:Receptors, LHRH / Q000378:metabolism
D009842:Oligopeptides; D011966:Receptors, LHRH; D007987:Gonadotropin-Releasing Hormone; C423508:abarelix